Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there…
Browsing: Acute Lymphoblastic Leukemia
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO)…
What is the latest news on lung cancer immunotherapies? On location at ASCO 2016, lung cancer expert Dr. Charu Aggarwal…
Dr. Laura Chow discusses new combination therapies and molecularly targeted therapies, specifically in head and neck cancers.
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
Robert Dreicer, MD at University of Virginia Health System talks about how the Atezolizumab FDA approval will spur more studies…
Heather Wakelee, MD at The Stanford University Medical Center outlines the therapeutic options currently available for RET altered NSCLC from…
Alexander Spira, MD of Virginia Cancer Specialists goes over the future of Next-Gen sequencing and who will respond and who…
Nathan Pennell, MD at Cleveland Clinic discusses how to chose the most effective second line PD-1 or PD-L1 therapy in…
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
Omid Hamid, MD at The Angeles Clinic Combi-d and BRIM7 trials and the extended follow-up results
Arjun Balar, MD of NYU Langone gives an overview of IMvigor 210 cohort one data and results
Justin Stebbing, MD, MA, FRCP, FRCPath, PhD from Imperial College Healthcare NHS Trust, London, UK discusses developments in anti-PD-1 and…
Dr. Evan Yu, MD of University of Washington School of Medicine notes that smoking does not predispose higher response rate…
Dr. Heather Wakelee, MD of The Stanford University Medical Center Wakelee_MET in NSCLC including its over expression increased copy number…
Bruce Johnson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the challenges associated with developing effective treatments for patients with…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the cost of drugs in multiple myeloma (MM) and the…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses highlights in multiple myeloma (MM) at the American Society of…
Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the place of nivolumab and pembrolizumab…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of…
Alexander Spira, MD of Virginia Cancer Specialists discusses mutation load and gene profiles appear to have a significant impact on…
Dr. Robert Dreicer, MD of the University of Virginia Health System gives an overview of PD-L1 expression on cancer cells…
Arjun Balar, MD of New York University Langone comments on deficient mismatch repair within urothelial cancer
Dr. Evan Yu, MD of the University of Washington School of Medicine outlines the IMvigor210 trial design and patient populaiton
Dr. Heather Wakelee, MD at The Stanford University Medical Center remarks on the E1505 trial results from ASCO 2016
Alexander Spira, MD of Virginia Cancer Specialist remarks on the many different combinations of immunotherapy drugs that are being being…
Omid Hamid, MD Director of the Melanoma Center at The Angeles Clinic goes over the advantages and disadvantages with Binimetinib…
Dr Robert Dreicer, MD of University of Virginia Health System highlights the importance of the FDA approval of Atezolizumab at…
Dr. Arjun Balar, MD of NYU Langone Medical Center discusses Bevacizumab in combination with chemotherapy in metastatic urothelial cancer at…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses his highlights for chronic…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the safety of idelalisib…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ discusses the issue of drug affordability and access in multiple…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of his…
Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ talks about his highlights from the American Society of Oncology (ASCO)…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ summarizes the results of two Phase III trials of daratumumab…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI shares some key Twitter tips for hematologists. Some of…
Sagar Lonial, MD from the Emory University Winship Cancer Institute, Atlanta, GA gives an overivew of the session ‘Are We…
Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ discusses updates to the Phase III PERSIST-1 trial of pacritinib for…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI discusses why hematologists should use social media. First Dr…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI talks about the quality of the ASCO and ASH…
Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA outlines the side effects that may occur in chronic…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of his talk on the management and…
Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of her talk on targeted therapy…
Elias Jabbour, MD from the The University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of the…
Anas Younes, MD of Memorial Sloan Kettering Cancer Center, New York, NY talks about Checkmate 205, a registrational trial of…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA discusses highlights on the in vivo drug screening session in…
Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore discusses the current status…